StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics cash

Cash and short-term investments held at the end of each period.

Halozyme Therapeutics's cash was $163.14M at Jun 30, 2026. For fiscal 2025 it was $133.82M, up 15.5% from the year before. Over ten years it grew 11.8% a year on average. The highest annual figure on record is $741.42M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$133.82M+15.5%
FY2024Dec 31, 2024$115.85M-2.1%
FY2023Dec 31, 2023$118.37M-67.4%
FY2022Dec 31, 2022$363.29M-51.0%
FY2021Dec 31, 2021$741.42M+101.2%
FY2020Dec 31, 2020$368.51M-12.6%
FY2019Dec 31, 2019$421.76M+621.8%
FY2018Dec 31, 2018$58.44M-65.5%
FY2017Dec 31, 2017$169.24M+151.6%
FY2016Dec 31, 2016$67.26M+53.6%
FY2015Dec 31, 2015$43.79M-29.2%
FY2014Dec 31, 2014$61.89M+126.2%
FY2013Dec 31, 2013$27.36M-72.5%
FY2012Dec 31, 2012$99.50M+90.0%
FY2011Dec 31, 2011$52.38M-36.7%
FY2010Dec 31, 2010$82.76M+22.7%
FY2009Dec 31, 2009$67.46M+5.9%
FY2008Dec 31, 2008$63.72M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$163.14M+163.7%
Q1 FY2026Mar 31, 2026$309.75M+75.7%
Q4 FY2025Dec 31, 2025$133.82M+15.5%
Q3 FY2025Sep 30, 2025$419.67M+171.9%
Q2 FY2025Jun 30, 2025$61.86M-67.1%
Q1 FY2025Mar 31, 2025$176.33M+7.1%
Q4 FY2024Dec 31, 2024$115.85M-2.1%
Q3 FY2024Sep 30, 2024$154.32M-43.7%
Q2 FY2024Jun 30, 2024$187.86M-15.1%
Q1 FY2024Mar 31, 2024$164.63M-40.4%
Q4 FY2023Dec 31, 2023$118.37M-67.4%
Q3 FY2023Sep 30, 2023$274.23M+3.1%
Q2 FY2023Jun 30, 2023$221.17M+5.4%
Q1 FY2023Mar 31, 2023$276.11M-64.9%
Q4 FY2022Dec 31, 2022$363.29M-51.0%
Q3 FY2022Sep 30, 2022$266.08M-67.4%
Q2 FY2022Jun 30, 2022$209.86M-72.2%
Q1 FY2022Mar 31, 2022$786.64M+2.9%
Q4 FY2021Dec 31, 2021$741.42M+101.2%
Q3 FY2021Sep 30, 2021$816.42M+135.1%
Q2 FY2021Jun 30, 2021$755.81M+95.8%
Q1 FY2021Mar 31, 2021$764.81M+626.2%
Q4 FY2020Dec 31, 2020$368.51M-12.6%
Q3 FY2020Sep 30, 2020$347.21M+481.6%
Q2 FY2020Jun 30, 2020$385.95M+471.4%
Q1 FY2020Mar 31, 2020$105.32M+72.4%
Q4 FY2019Dec 31, 2019$421.76M+621.8%
Q3 FY2019Sep 30, 2019$59.70M+7.5%
Q2 FY2019Jun 30, 2019$67.54M+21.3%
Q1 FY2019Mar 31, 2019$61.10M-38.0%
Q4 FY2018Dec 31, 2018$58.44M-65.5%
Q3 FY2018Sep 30, 2018$55.52M-66.3%
Q2 FY2018Jun 30, 2018$55.67M-51.5%
Q1 FY2018Mar 31, 2018$98.51M-14.5%
Q4 FY2017Dec 31, 2017$169.24M+151.6%
Q3 FY2017Sep 30, 2017$164.90M+167.2%
Q2 FY2017Jun 30, 2017$114.75M–
Q1 FY2017Mar 31, 2017$115.25M–
Q4 FY2016Dec 31, 2016$67.26M–
Q3 FY2016Sep 30, 2016$61.71M–

More Halozyme Therapeutics figures

See a number that looks wrong?